GLP-1 receptor agonists for secondary prevention after myocardial infarction and stroke in type 2 diabetes: nationwide real-world evidence - Scorecard - MDSpire
Advertisement
GLP-1 receptor agonists for secondary prevention after myocardial infarction and stroke in type 2 diabetes: nationwide real-world evidence
Clinical Scorecard: Efficacy of GLP-1 Receptor Agonists in Preventing Cardiovascular Events Post-Myocardial Infarction and Stroke in Individuals with Type 2 Diabetes: Insights from a Nationwide Registry Study
At a Glance
Category
Detail
Condition
Type 2 diabetes with prior myocardial infarction or ischemic stroke
Key Mechanisms
GLP-1 receptor agonists reduce cardiovascular risk via glucose lowering, weight loss, blood pressure reduction, and anti-atherosclerotic effects without increasing hypoglycemia risk
Target Population
Patients with Type 2 diabetes surviving myocardial infarction or ischemic stroke
Care Setting
Secondary prevention in outpatient and post-hospitalization clinical practice
Key Highlights
GLP-1RA therapy initiated within 12 months post-MI or stroke reduced major adverse cardiovascular events (MACE) by approximately 30%.
GLP-1RA use was associated with 40–45% lower all-cause and cardiovascular mortality in real-world practice.
Despite benefits, GLP-1RA utilization was low (~2%) among eligible patients, with disparities by age and sex.
Guideline-Based Recommendations
Diagnosis
Identify patients with Type 2 diabetes and established atherosclerotic cardiovascular disease post-MI or ischemic stroke.
Management
Initiate GLP-1 receptor agonist therapy in patients with T2D and established ASCVD regardless of glycemic control.
Incorporate GLP-1RA as part of secondary prevention to reduce recurrent cardiovascular events and mortality.
Monitoring & Follow-up
Monitor cardiovascular outcomes and mortality during follow-up after initiation of GLP-1RA therapy.
Assess for equitable access and adherence, especially in older adults and women.
Risks
GLP-1RA therapy has a favorable safety profile without increased hypoglycemia risk.
Patient & Prescribing Data
Survivors of myocardial infarction or ischemic stroke with Type 2 diabetes in the Czech Republic (2015–2024)
Only about 2% of eligible patients initiated GLP-1RA therapy within 12 months post-event; initiation was associated with significant reductions in MACE and mortality but disparities in prescribing exist by age and sex.
Clinical Best Practices
Prioritize initiation of GLP-1RA therapy in T2D patients after MI or ischemic stroke to reduce recurrent cardiovascular events and mortality.
Address barriers to prescribing to improve uptake, especially among women and older adults.
Use nationwide registry data to monitor real-world effectiveness and equity in GLP-1RA utilization.
Educate clinicians on guideline recommendations endorsing GLP-1RA for secondary prevention in T2D with ASCVD.
by Petra Sedova, Michal Vrablík, Petr Kala, Petr Ošťádal, Aleš Tichopád, Aleš Tomek, Robert Mikulik, Gleb Donin, Simona Littnerová, Julia Anna Kent, Jiří Jarkovsky, Virend K Somers, Robert D Brown
